恩度联合DP化疗方案治疗晚期非小细胞肺癌的临床研究

目的探讨恩度联合DP化疗方案(多西紫杉醇+顺铂)治疗晚期非小细胞肺癌患者的近期临床疗效,评价其临床应用的安全性和耐受性。方法 45例晚期非小细胞肺癌患者给予DP方案化疗同时联合恩度7.5 mg/m2,连用2周后暂停1周为1周期,至少完成2周期,观察近期疗效、疾病进展时间及不良反应。结果 45例患者中部分缓解18例(40.0%),稳定17例(37.8%),进展10例(22.2%),有效率为40.0%,临床受益率为77.8%。不良反应主要为骨髓抑制和胃肠反应,患者经对症处理后可以耐受。结论恩度联合含铂类DP化疗方案一线治疗晚期非小细胞肺癌是一种安全有效的方案。

A feasibility study of endostar combined with platinum-based DP chemotherapy in the treatment of advanced non-small cell lung cancer

Objective To evaluate the short-term therapeutic efficacy and safety of endostar combined with platinum-based DP(Docetaxel and Platinum) chemotherapy for patients with advanced non-small cell lung cancer(NSCLC).Methods Forty-five patients with histopathologically confirmed advanced NSCLC enrolled in this study received endostar plus DP regimen(endostar 7.5 mg/m2 day 1 to 14,repeated 21 days).All patients should complete 2 cycles at least.Results Of 45 patients enrolled in this study,the overall response rate and the clinical benefit rate was 40.0% and 77.8% respectively,i.e.,18(40.0%) patients with PR,17(37.8%) with SD and 10(22.2%) with PD.The main side effects of myelosuppression toxicity and nausea/vomiting were usually tolerable after symptomatic treatment.Conclusion Administration of endostar combined with platinum-based DP chemotherapy for advanced NSCLC patients has a reliable short-term curative effect and low side effects,suggesting its potential worth for clinical application.